top of page

iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy

Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for iQure-007, its novel therapeutic currently in development for the treatment of epilepsy.


“We are delighted with this second patent being granted for iQ-007,” said iQure Chief Executive Officer Pawel Zolnierczyk. “This is an important step in the process of commercializing this promising asset for the treatment of Drug Resistant Epilepsy. Patent protections are pivotal to maintaining the value of our assets. With the award of this second patent, we now have expanded protection and even better potential for securing market position.”


Recent experiments confirmed that iQ-007 acts as a positive allosteric modulator of naturally occurring neuromodulator EAAT2. Through this unique mechanism, it enhances the natural glutamate uptake preventing neurotoxicity, associated with epilepsy and neuropathic pain.



About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

85 views0 comments

Recent Posts

See All

Comments


bottom of page